title: Oral magnesium supplementation decreases C-reactive protein levels in subjects with prediabetes and hypomagnesemia: a clinical randomized double-blind placebo-controlled trial.
abstract: OBJECTIVE
  It has been suggested that magnesium deficiency is associated with the triggering of acute phase response, which may contribute to type 2 diabetes and cardiovascular disease risk. We undertook this study to determine whether oral magnesium supplementation modifies serum levels of high-sensitivity C-reactive protein (hsCRP) in apparently healthy subjects with prediabetes and hypomagnesemia.
  
  
  METHODS
  A total of 62 men and non-pregnant women aged 18-65 year, with new diagnosis of prediabetes (glucose 5.6 <7.0 mmol/L and/or post-load glucose ≥7.7 <11.1 mmol/L) and hypomagnesemia (serum magnesium levels <0.74 mmol/L) were enrolled in a clinical double-blind placebo-controlled trial and randomly allocated to receive either magnesium chloride (30 mL of MgCl2 5% solution) or NaHCO3 0.1% solution, once daily for 3 months.
  
  
  RESULTS
  At basal conditions, anthropometric and biochemical variables were similarly distributed in both groups. At the end of follow-up, participants who received magnesium chloride showed higher serum magnesium levels (0.86 ± 0.08 vs. 0.69 ± 0.16 mmol/L, p = 0.002) and lower hsCRP levels (4.8 ± 15.2 vs. 17.1 ± 21.0 nmol/L, p = 0.01) compared with participants in the control group.
  
  
  CONCLUSIONS
  Oral magnesium supplementation decreases hsCRP levels in apparently healthy subjects with prediabetes and hypomagnesemia.
authors.affiliation: Biomedical Research Unit, Mexican Social Security Institute, Durango, Mexico; The Research Group on Diabetes, Durango, Mexico.
authors.forename: Luis E
authors.initials: LE
authors.lastname: Simental-Mendía
authors.affiliation: Biomedical Research Unit, Mexican Social Security Institute, Durango, Mexico; The Research Group on Diabetes, Durango, Mexico.
authors.forename: Martha
authors.initials: M
authors.lastname: Rodríguez-Morán
authors.affiliation: Biomedical Research Unit, Mexican Social Security Institute, Durango, Mexico; The Research Group on Diabetes, Durango, Mexico. Electronic address: guerrero.romero@hotmail.com.
authors.forename: Fernando
authors.initials: F
authors.lastname: Guerrero-Romero
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D002097:C-Reactive Protein / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D053565:Hypercalciuria / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D015636:Magnesium Chloride / Q000008:administration & dosage* / Q000097:blood; D008297:Male; D008875:Middle Aged; D009397:Nephrocalcinosis / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D011236:Prediabetic State / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D015499:Renal Tubular Transport, Inborn Errors / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D055815:Young Adult
chemical_list: D015636:Magnesium Chloride; D002097:C-Reactive Protein
keywords: C-reactive protein; Hypomagnesemia; Magnesium; Prediabetes